In a win for Regeneron, Novartis' syringe for AMD drug declared 'unpatentable'

In a win for Regeneron, Novartis' syringe for AMD drug declared 'unpatentable'

Source: 
Endpoints
snippet: 

Regeneron has won a patent case against Swiss pharma giant Novartis over the delivery system for its eye drug Eylea.

The US Patent Trial and Appeal Board ruled that Novartis’ pre-filled syringe for injecting its eye medication Lucentis was “unpatentable” and handed the victory to Regeneron and its AMD drug Eylea.